Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	12/6/2005 12:44:27 PM
	of 312

Par, Three Rivers Get FDA OK on Ribasphere Monday December 5, 4:00 pm ET Par Pharmaceutical, Three Rivers Pharmaceuticals Say FDA Approves Hepatitis C Treatment SPRING VALLEY, N.Y. (AP) -- Drug companies Par Pharmaceutical Cos. and privately held Three Rivers Pharmaceuticals LLC said Monday that the Food and Drug Administration approved their Ribasphere hepatitis C treatment. The agency approved Ribasphere in 200 milligram, 400 milligram and 600 milligram tablets for use with interferon alfa-2a to treat hepatitis C. The product uses the active ingredient ribavirin used in Copegus. The pharmaceuticals unit of Swiss drug maker Roche Holdings Ltd. makes Copegus, a drug with about $200 million in annual U.S. sales. Par shares fell 27 cents to $26.13 in afternoon trading on the New York Stock Exchange. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next